SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/26/24 AbbVie Inc. 424B5 2:764K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 424B5 Prospectus - Primary Offering or Shelf Securities HTML 706K - New Facts or Events 2: EX-FILING FEES Filing Fees HTML 27K
tm246405-2_424b5 - none - 9.098032s |
| | |
Public
offering price(1) |
| |
Underwriting
discount |
| |
Proceeds, before
expenses, to us |
| |||||||||
Per 2027 Note
|
| | | | 99.859% | | | | | | 0.250% | | | | | | 99.609% | | |
Per 2029 Note
|
| | | | 99.793% | | | | | | 0.350% | | | | | | 99.443% | | |
Per 2031 Note
|
| | | | 99.896% | | | | | | 0.400% | | | | | | 99.496% | | |
Per 2034 Note
|
| | | | 99.685% | | | | | | 0.450% | | | | | | 99.235% | | |
Per 2044 Note
|
| | | | 99.862% | | | | | | 0.750% | | | | | | 99.112% | | |
Per 2054 Note
|
| | | | 99.657% | | | | | | 0.875% | | | | | | 98.782% | | |
Per 2064 Note
|
| | | | 99.626% | | | | | | 0.875% | | | | | | 98.751% | | |
Totals
|
| | | $ | 14,963,187,500 | | | | | $ | 80,875,000 | | | | | $ | 14,882,312,500 | | |
|
Morgan Stanley
(All Notes)
|
| |
J.P. Morgan
(All Notes)
|
| |
BofA Securities
(All Notes)
|
| |
Citigroup
(All Notes)
|
|
|
Barclays
(2054 Notes, 2064 Notes)
|
| |
BNP PARIBAS
(2044 Notes, 2054 Notes)
|
| |
HSBC
(2027 Notes, 2034 Notes)
|
|
|
Deutsche Bank Securities
(2034 Notes, 2044 Notes)
|
| |
SOCIETE GENERALE
(2027 Notes, 2031 Notes)
|
| |
Mizuho
(2029 Notes, 2031 Notes)
|
| |
Wells Fargo Securities
(2029 Notes, 2064 Notes)
|
|
|
Barclays
(2027 Notes, 2029 Notes, 2031
Notes, 2034 Notes, 2044 Notes) |
| |
BNP PARIBAS
(2027 Notes, 2029 Notes, 2031
Notes, 2034 Notes, 2064 Notes) |
| |
HSBC
(2029 Notes, 2031 Notes, 2044
Notes, 2054 Notes, 2064 Notes) |
|
|
Deutsche Bank Securities
(2027 Notes, 2029 Notes, 2031
Notes, 2054 Notes, 2064 Notes) |
| |
SOCIETE GENERALE
(2029 Notes, 2034 Notes, 2044
Notes, 2054 Notes, 2064 Notes) |
| |
Mizuho
(2027 Notes, 2034 Notes, 2044
Notes, 2054 Notes, 2064 Notes) |
| |
Wells Fargo Securities
(2027 Notes, 2031 Notes, 2034
Notes, 2044 Notes, 2054 Notes) |
|
|
MUFG
|
| |
US Bancorp
|
| |
Lloyds Securities
|
| |
Santander
|
|
|
TD Securities
|
| |
Siebert Williams Shank
|
| |
R. Seelaus & Co., LLC
|
|
|
CastleOak Securities, L.P.
|
| |
Ramirez & Co., Inc.
|
| |
Drexel Hamilton
|
|
| | |
Page
|
| |||
PROSPECTUS SUPPLEMENT
|
| | | | | | |
| | | | S-1 | | | |
| | | | S-2 | | | |
| | | | S-13 | | | |
| | | | S-17 | | | |
| | | | S-18 | | | |
| | | | S-20 | | | |
| | | | S-36 | | | |
| | | | S-41 | | | |
| | | | S-48 | | | |
| | | | S-48 | | | |
| | | | S-49 | | | |
| | | | S-50 | | | |
| | | | S-51 | | | |
| | | | S-51 | | |
| | |
Page
|
| |||
PROSPECTUS
|
| | | | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 10 | | | |
| | | | 12 | | | |
Experts | | | | | 12 | | |
Condition
|
| |
Principal Markets
|
|
Rheumatoid arthritis (moderate to severe) | | | North America, European Union | |
Psoriatic arthritis | | | North America, European Union | |
Ankylosing spondylitis | | | North America, European Union | |
Adult Crohn’s disease (moderate to severe) | | | North America, European Union | |
Plaque psoriasis (moderate to severe chronic) | | | North America, European Union | |
Juvenile idiopathic arthritis (moderate to severe polyarticular)
|
| | North America, European Union | |
Ulcerative colitis (moderate to severe) | | | North America, European Union | |
Axial spondyloarthropathy | | | European Union | |
Pediatric Crohn’s disease (moderate to severe) | | | North America, European Union | |
Hidradenitis suppurativa (moderate to severe) | | | North America, European Union | |
Pediatric enthesitis-related arthritis | | | European Union | |
Condition
|
| |
Principal Markets
|
|
Non-infectious intermediate, posterior and panuveitis | | | North America, European Union | |
Pediatric ulcerative colitis (moderate to severe) | | | U.S., Canada, European Union | |
Pediatric uveitis | | | North America, European Union | |
Condition
|
| |
Principal Markets
|
|
Plaque psoriasis (moderate to severe) | | | North America, European Union, Japan | |
Psoriatic arthritis | | | U.S., European Union | |
Crohn’s disease (moderate to severe) | | | U.S., Canada, European Union | |
Condition
|
| |
Principal Markets
|
|
Rheumatoid arthritis (moderate to severe) | | | North America, European Union, Japan | |
Psoriatic arthritis | | | U.S., Canada, European Union, Japan | |
Ankylosing spondylitis | | | U.S., European Union | |
Atopic dermatitis (moderate to severe) | | | U.S., Canada, European Union, Japan | |
Axial spondyloarthropathy | | | U.S., European Union | |
Ulcerative colitis (moderate to severe) | | | U.S., European Union | |
Crohn’s disease (moderate to severe) | | | U.S., European Union | |
| | |
As of December 31, 2023
|
| |||||||||
(dollars in millions)
|
| |
Actual
|
| |
As Adjusted
|
| ||||||
Cash and equivalents
|
| | | $ | 12,814 | | | | | $ | 12,274(a) | | |
Total debt and lease obligations: | | | | | | | | | | | | | |
Commercial paper(b)
|
| | | | — | | | | | | — | | |
Revolving credit facility (up to $5 billion)
|
| | | | — | | | | | | — | | |
Term loan facility
|
| | | | 2,000 | | | | | | 2,000 | | |
New term loan facility(b)
|
| | | | — | | | | | | — | | |
3.75% senior notes due 2023
|
| | | | — | | | | | | — | | |
1.50% senior euro notes due 2023 (€500 principal)
|
| | | | — | | | | | | — | | |
2.60% senior notes due 2024
|
| | | | 3,750 | | | | | | 3,750 | | |
1.375% senior euro notes due 2024 (€1,450 principal)(c)(d)
|
| | | | 1,610 | | | | | | 1,610 | | |
3.85% senior notes due 2024
|
| | | | 1,032 | | | | | | 1,032 | | |
1.25% senior euro notes due 2024 (€700 principal)(c)(d)
|
| | | | 777 | | | | | | 777 | | |
3.60% senior notes due 2025
|
| | | | 3,750 | | | | | | 3,750 | | |
3.80% senior notes due 2025
|
| | | | 3,021 | | | | | | 3,021 | | |
2.95% senior notes due 2026
|
| | | | 4,000 | | | | | | 4,000 | | |
3.20% senior notes due 2026
|
| | | | 2,000 | | | | | | 2,000 | | |
0.75% senior euro notes due 2027 (€750 principal)(c)
|
| | | | 833 | | | | | | 833 | | |
4.800% senior notes due 2027
|
| | | | — | | | | | | 2,250 | | |
4.25% senior notes due 2028
|
| | | | 1,750 | | | | | | 1,750 | | |
2.125% senior euro notes due 2028 (€750 principal)(c)
|
| | | | 833 | | | | | | 833 | | |
2.625% senior euro notes due 2028 (€500 principal)(c)
|
| | | | 555 | | | | | | 555 | | |
3.20% senior notes due 2029
|
| | | | 5,500 | | | | | | 5,500 | | |
2.125% senior euro notes due 2029 (€550 principal)(c)
|
| | | | 611 | | | | | | 611 | | |
4.800% senior notes due 2029
|
| | | | — | | | | | | 2,500 | | |
1.25% senior euro notes due 2031 (€650 principal)(c)
|
| | | | 722 | | | | | | 722 | | |
4.950% senior notes due 2031
|
| | | | — | | | | | | 2,000 | | |
5.050% senior notes due 2034
|
| | | | — | | | | | | 3,000 | | |
4.55% senior notes due 2035
|
| | | | 1,789 | | | | | | 1,789 | | |
4.50% senior notes due 2035
|
| | | | 2,500 | | | | | | 2,500 | | |
4.30% senior notes due 2036
|
| | | | 1,000 | | | | | | 1,000 | | |
| | |
As of December 31, 2023
|
| |||||||||
(dollars in millions)
|
| |
Actual
|
| |
As Adjusted
|
| ||||||
4.05% senior notes due 2039
|
| | | | 4,000 | | | | | | 4,000 | | |
4.40% senior notes due 2042
|
| | | | 2,600 | | | | | | 2,600 | | |
4.625% senior notes due 2042
|
| | | | 457 | | | | | | 457 | | |
4.85% senior notes due 2044
|
| | | | 1,074 | | | | | | 1,074 | | |
5.350% senior notes due 2044
|
| | | | — | | | | | | 750 | | |
4.70% senior notes due 2045
|
| | | | 2,700 | | | | | | 2,700 | | |
4.75% senior notes due 2045
|
| | | | 881 | | | | | | 881 | | |
4.45% senior notes due 2046
|
| | | | 2,000 | | | | | | 2,000 | | |
4.875% senior notes due 2048
|
| | | | 1,750 | | | | | | 1,750 | | |
4.25% senior notes due 2049
|
| | | | 5,750 | | | | | | 5,750 | | |
5.400% senior notes due 2054
|
| | | | — | | | | | | 3,000 | | |
5.500% senior notes due 2064
|
| | | | — | | | | | | 1,500 | | |
Fair value hedges
|
| | | | (266) | | | | | | (266) | | |
Unamortized bond discounts
|
| | | | (106) | | | | | | (143) | | |
Unamortized deferred financing costs
|
| | | | (198) | | | | | | (301) | | |
Unamortized bond premiums
|
| | | | 668 | | | | | | 668 | | |
Other
|
| | | | 42 | | | | | | 42 | | |
Stockholders’ equity
|
| | | | 10,360 | | | | | | 10,360 | | |
Total capitalization
|
| | | $ | 69,745 | | | | | $ | 84,605 | | |
|
Underwriter
|
| |
Principal
Amount of 2027 Notes |
| |
Principal
Amount of 2029 Notes |
| |
Principal
Amount of 2031 Notes |
| |
Principal
Amount of 2034 Notes |
| |
Principal
Amount of 2044 Notes |
| |
Principal
Amount of 2054 Notes |
| |
Principal
Amount of 2064 Notes |
| |||||||||||||||||||||
Morgan Stanley & Co. LLC
|
| | | $ | 337,500,000 | | | | | $ | 375,000,000 | | | | | $ | 300,000,000 | | | | | $ | 450,000,000 | | | | | $ | 112,500,000 | | | | | $ | 450,000,000 | | | | | $ | 225,000,000 | | |
J.P. Morgan Securities LLC
|
| | | | 337,500,000 | | | | | | 375,000,000 | | | | | | 300,000,000 | | | | | | 450,000,000 | | | | | | 112,500,000 | | | | | | 450,000,000 | | | | | | 225,000,000 | | |
BofA Securities, Inc.
|
| | | | 337,500,000 | | | | | | 375,000,000 | | | | | | 300,000,000 | | | | | | 450,000,000 | | | | | | 112,500,000 | | | | | | 450,000,000 | | | | | | 225,000,000 | | |
Citigroup Global Markets Inc.
|
| | | | 121,500,000 | | | | | | 135,000,000 | | | | | | 108,000,000 | | | | | | 162,000,000 | | | | | | 40,500,000 | | | | | | 162,000,000 | | | | | | 81,000,000 | | |
Barclays Capital Inc.
|
| | | | 121,500,000 | | | | | | 135,000,000 | | | | | | 108,000,000 | | | | | | 162,000,000 | | | | | | 40,500,000 | | | | | | 162,000,000 | | | | | | 81,000,000 | | |
BNP Paribas Securities Corp.
|
| | | | 121,500,000 | | | | | | 135,000,000 | | | | | | 108,000,000 | | | | | | 162,000,000 | | | | | | 40,500,000 | | | | | | 162,000,000 | | | | | | 81,000,000 | | |
HSBC Securities (USA) Inc.
|
| | | | 121,500,000 | | | | | | 135,000,000 | | | | | | 108,000,000 | | | | | | 162,000,000 | | | | | | 40,500,000 | | | | | | 162,000,000 | | | | | | 81,000,000 | | |
Deutsche Bank Securities Inc.
|
| | | | 121,500,000 | | | | | | 135,000,000 | | | | | | 108,000,000 | | | | | | 162,000,000 | | | | | | 40,500,000 | | | | | | 162,000,000 | | | | | | 81,000,000 | | |
SG Americas Securities, LLC
|
| | | | 121,500,000 | | | | | | 135,000,000 | | | | | | 108,000,000 | | | | | | 162,000,000 | | | | | | 40,500,000 | | | | | | 162,000,000 | | | | | | 81,000,000 | | |
Mizuho Securities USA LLC
|
| | | | 121,500,000 | | | | | | 135,000,000 | | | | | | 108,000,000 | | | | | | 162,000,000 | | | | | | 40,500,000 | | | | | | 162,000,000 | | | | | | 81,000,000 | | |
Wells Fargo Securities, LLC
|
| | | | 121,500,000 | | | | | | 135,000,000 | | | | | | 108,000,000 | | | | | | 162,000,000 | | | | | | 40,500,000 | | | | | | 162,000,000 | | | | | | 81,000,000 | | |
MUFG Securities Americas Inc.
|
| | | | 44,100,000 | | | | | | 49,000,000 | | | | | | 39,200,000 | | | | | | 58,800,000 | | | | | | 14,700,000 | | | | | | 58,800,000 | | | | | | 29,400,000 | | |
U.S. Bancorp Investments, Inc.
|
| | | | 44,100,000 | | | | | | 49,000,000 | | | | | | 39,200,000 | | | | | | 58,800,000 | | | | | | 14,700,000 | | | | | | 58,800,000 | | | | | | 29,400,000 | | |
Lloyds Securities Inc.
|
| | | | 44,100,000 | | | | | | 49,000,000 | | | | | | 39,200,000 | | | | | | 58,800,000 | | | | | | 14,700,000 | | | | | | 58,800,000 | | | | | | 29,400,000 | | |
Santander US Capital Markets LLC
|
| | | | 44,100,000 | | | | | | 49,000,000 | | | | | | 39,200,000 | | | | | | 58,800,000 | | | | | | 14,700,000 | | | | | | 58,800,000 | | | | | | 29,400,000 | | |
TD Securities (USA) LLC
|
| | | | 44,100,000 | | | | | | 49,000,000 | | | | | | 39,200,000 | | | | | | 58,800,000 | | | | | | 14,700,000 | | | | | | 58,800,000 | | | | | | 29,400,000 | | |
Siebert Williams Shank & Co., LLC
|
| | | | 22,500,000 | | | | | | 25,000,000 | | | | | | 20,000,000 | | | | | | 30,000,000 | | | | | | 7,500,000 | | | | | | 30,000,000 | | | | | | 15,000,000 | | |
R. Seelaus & Co., LLC
|
| | | | 5,625,000 | | | | | | 6,250,000 | | | | | | 5,000,000 | | | | | | 7,500,000 | | | | | | 1,875,000 | | | | | | 7,500,000 | | | | | | 3,750,000 | | |
CastleOak Securities, L.P.
|
| | | | 5,625,000 | | | | | | 6,250,000 | | | | | | 5,000,000 | | | | | | 7,500,000 | | | | | | 1,875,000 | | | | | | 7,500,000 | | | | | | 3,750,000 | | |
Samuel A. Ramirez & Company, Inc.
|
| | | | 5,625,000 | | | | | | 6,250,000 | | | | | | 5,000,000 | | | | | | 7,500,000 | | | | | | 1,875,000 | | | | | | 7,500,000 | | | | | | 3,750,000 | | |
Drexel Hamilton, LLC
|
| | | | 5,625,000 | | | | | | 6,250,000 | | | | | | 5,000,000 | | | | | | 7,500,000 | | | | | | 1,875,000 | | | | | | 7,500,000 | | | | | | 3,750,000 | | |
Total | | | | $ | 2,250,000,000 | | | | | $ | 2,500,000,000 | | | | | $ | 2,000,000,000 | | | | | $ | 3,000,000,000 | | | | | $ | 750,000,000 | | | | | $ | 3,000,000,000 | | | | | $ | 1,500,000,000 | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 10 | | | |
| | | | 12 | | | |
| | | | 12 | | |
This ‘424B5’ Filing | Date | Other Filings | ||
---|---|---|---|---|
3/15/34 | ||||
12/15/33 | ||||
3/15/31 | ||||
1/15/31 | ||||
3/15/29 | ||||
2/15/29 | ||||
3/15/27 | ||||
2/15/27 | ||||
6/3/25 | ||||
3/5/25 | ||||
12/5/24 | ||||
9/15/24 | ||||
9/6/24 | ||||
Filed on: | 2/26/24 | |||
2/22/24 | FWP, S-8 | |||
2/12/24 | 8-K | |||
12/31/23 | 10-K, 4 | |||
12/30/23 | ||||
12/21/23 | ||||
12/6/23 | 8-K | |||
11/30/23 | 8-K | |||
11/14/22 | ||||
2/23/22 | ||||
2/22/22 | 4, S-3ASR | |||
12/31/21 | 10-K, 11-K, 4, SD | |||
1/2/13 | 8-K, EFFECT | |||
1/1/13 | ||||
11/8/12 | ||||
4/10/12 | ||||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/20/24 AbbVie Inc. 10-K 12/31/23 118:19M 2/20/24 AbbVie Inc. 8-K:5,7,9 2/14/24 12:323K Toppan Merrill/FA 3/20/23 AbbVie Inc. DEF 14A 12:7M Toppan Merrill Bridge/FA 2/17/23 AbbVie Inc. 10-K 12/31/22 120:24M 2/18/22 AbbVie Inc. 10-K 12/31/21 123:23M 3/22/21 AbbVie Inc. DEF 14A 5/07/21 1:3.9M Toppan Merrill Bridge/FA 2/19/21 AbbVie Inc. 10-K 12/31/20 117:22M |